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Summary: We evaluated the clinical performances of the immunoenzymometric assays for type I collagen N-
terminal and C-terminal telopeptides and the HPLC assay for total deoxypyridinoline, in distinguishing between
subjects with a moderately increased bone resorption rate (women in postmenopause) and subjects with normal
bone resorption rate (women in premenopause). The postmenopausal group consisted of 61 women who had been
in menopause for no more than 10 years, while the premenopausal group consisted of 52 healthy women with
normal menstrual cycles. The biochemical markers were measured in a 24 hour urine sample and the results
expressed as the molar ratio with urinary creatinine. The clinical performances were estimated by calculating the
accuracy (as the area under a Receiver Operated Characteristic (ROC) curve: mean ± SEM) and the discriminating
power (as score) of each assay in distinguishing postmenopausal subjects from premenopausal subjects. Type I
collagen C-terminal telopeptide, type I collagen N-terminal telopeptide and total deoxypyridinoline were signifi-
cantly higher in the postmenopausal than in the premenopausal group (p < 0.001). Accuracies of these three markers
ranged from 66.8 ± 5.1% to 76.8 ± 4.3%, while Z scores ranged from 3.54 to 5.67. Type I collagen C-terminal
telopeptide, type I collagen N-terminal telopeptide and total deoxypyridinoline were not significantly different in
their accuracy or discriminating power. All markers were highly correlated with coefficients of correlation ranging
from 0.61 to 0.77.
In summary, this study shows that
1) the immunoenzymometric assays for type I collagen N-terminal telopeptide and type I collagen C-terminal
telopeptide show a high accuracy and disciminating power in distinguishing subjects with different bone resorp-
tion rate;
2) the results obtained with these immunoenzymometric assays are comparable to those obtained with the HPLC
assay for total deoxypyridinoline.
In conclusion our data support the use of the immunoenzymometric assays for type I collagen N-terminal telopeptide
and type I collagen C-terminal telopeptide for estimating bone resorption.
Introduction dinium cross-links were shown to be relatively efficient
The use of biochemical markers of bone resorption in estimating both s™n and biS differences in bone re-
seems increasingly important in the diagnosis and fol- sorP lon ra e ^ ' ''
low-up of metabolic bone diseases, particularly osteo- Unfortunately these assays, particularly the pyridinium
porosis. In a previous paper Bettica and colleagues (1) cross-links, are time-consuming (3), and an immunomet-
have shown that hydroxyproline, the time-honoured bio- ric assay is desirable. In recent months, different immu-
chemical marker of bone resorption, is adequate for dis- noenzymometric assays that measure type I collagen tel-
tinguishing subjects with large increases in bone resorp- opeptides (both C- and N-terminal) have been proposed
tion rate (Pagencs and children) from normal subjects, (4, 5), and preliminary data on these assays in different
but has limited use in estimating small differences in metabolic bone diseases have shown promising results
bone resorption rate (postmenopausal osteoporosis). On (4, 5). However, to the best of our knowledge, the clin-
the other hand, galactosyl hydroxylysine and the pyri- ical performances of these new assays have not yet been
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compared in the same subjects, in order to establish their
respective accuracies in discriminating different rates of
bone resorption.
This study sought to evaluate the clinical performances
of these new immunoenzymometric assays in compari-
son with those of the HPLC assay for total deoxy-
pyridinoline, and to estimate the relationships among
these markers.
Patients and Methods
Two groups of subjects were selected for the study. The control
group (premenopausal) consisted of 52 women with regular men-
strual cycle and regular ovulation (as demonstrated by a serum
progesterone level > 5 g/l around the 20th day of cycle) with an
age of 34.2 ±5.8 years (mean ± SD), recruited among the hospital
personnel; none of them had any disease or was taking any medica-
tion known to affect bone turnover. Their weight was 62.2 ±8.1
kg and their height 160.3 ± 11 cm. The second group (postmeno-
pausal) consisted of 61 women in postmenopause (< 10 years;
mean 7.1 ± 3.7 years) with an age of 57.3 ± 3.5 years, who
attended our Endocrinology Outpatient Clinic. Their weight was
61.4 ± 8.3 kg and their height 159.4 ± 5.5 cm. The bone mineral
density of the spine of the postmenopausal group (measured by
dual X-ray absorptiometry in the anteroposterior projection with a
QDR2000 bone densitometer, Hologic) was 0.821 ± 0.071 g/cm2,
corresponding to a t score of —2.31 ± 0.66 (calculated using the
normal young female Caucasian database provided by Hologic).
None of the subjects in the postmenopausal group was taking any
medication known to affect bone turnover.
All subjects collected a 24 hour urine sample and aliquots were
stored at -20 °C until use. Total deoxypyridinoline, type I collagen
N-terminal telopeptide, type I collagen C-terminal telopeptide and
creatinine were measured. All samples were measured in the same
run to avoid inter-assay variation.
Total deoxypyridinoline was measured by HPLC with a commer-
cial kit (Chrom-Links in HPLC, BIORAD). Type I collagen N-
terminal telopeptide was measured with a commercial kit with a
monoclonal antibody specific for the cross-linked type I collagen
N-terminal telopeptide (Osteomark, Ostex, USA). Type I collagen
C-terminal telopeptide was measured with a commercial kit
(Crosslaps ELISA, Osteometer, Denmark) with a polyclonal anti-
body raised against a synthetic sequence of type I collagen C-ter-
minal telopeptide. Creatinine was measured by an automatic assay
based on the Jaffe method.
Statistics
The clinical performances of the different markers were estimated
by calculating the accuracy and the discriminating power a distin-
guishing postmenopausal from premenopausal women (1). The ac-
curacy was calculated as the mean ± SEM area under a receiver
operated characteristic (ROC) curve that was drawn by calculating
the sensitivity and the false positive ratio at nine different threshold
values (6). The method used to select the threshold values was the
same for each assay. The values selected ranged from mean — 2 SD
to mean + 2 SD of the control subjects. The discriminating power
was calculated as the Z score with the aid of the following for-
mula (7):
Z score =
(postmenopausal mean — premenopausal mean)
(postmenopausal SD)2 (premenopausal SD)2
postmenopausal n premenopausal n
The accuracies of the different tests were compared by the method
of Hanley & McNeil (6). The relationships among the different
markers were estimated by linear regression analysis.
Finally, to test the agreement among total deoxypyridinoline,
type I collagen N-terminal telopeptide and type I collagen C-
terminal telopeptide, we calculated for each postmenopausal
woman and for each marker a t score (t score = (postmenopausal
subject value — premenopausal mean value)/premenopausal stan-
dard deviation) and for each pair of markers we estimated the
correlation between the mean t score (independent variable) and
the difference between the t scores (dependent variable) by the
method of Bland & Altman (8).
Results
As shown in figure 1 the urinary excretion of total de-
oxypyridinoline/creatinine, type I collagen N-terminal
telopeptide/creatinine and type I collagen C-terminal tel-
opeptide/creatinine was significantly higher in post-
menopausal women. The mean increase was 32% for
total deoxypyridinoline/creatinine, 31% for type I colla-
gen N-terminal telopeptide/creatinine and 65% for type I
collagen C-terminal telopeptide/creatinine.
Table 1 shows the clinical performances of the three
markers. The accuracies of total deoxypyridinoline/
creatinine, type I collagen N-terminal telopeptide/creat-
inine and type I collagen C-terminal telopeptide/creati-
nine were comparable and ranged from 66.8 ±5.1%
(type I collagen N-terminal telopeptide/creatinine) to
76.8 ± 5.3% (type I collagen C-terminal telopeptide/
creatinine). The discriminate powers ranged from 3.54
(type I collagen N-terminal telopeptide/creatinine) to
5.67 (type I collagen C-terminal telopeptide/creatinine).
The accuracies and discriminating powers were not
significantly different for each of the three markers.
As shown in table 2 all the markers were highly
correlated with coefficients of correlation ranging from
0.61 (total deoxypyridinoline vs type I collagen C-
terminal telopeptide) to 0.77 (total deoxypyridinoline
vs type I collagen N-terminal telopeptide) when the
absolute values were considered (tab. 2a), and from
0.502 (total deoxypyridinoline/creatinine vs type I col-
lagen C-terminal telopeptide/creatinine) to 0.681 (ty-
pe I collagen N-terminal telopeptide/creatinine vs ty-
pe I collagen C-terminal telopeptide/creatinine) when
creatinine ratios were used (tab. 2b). As shown in
figure 2 there was also a good agreement among the
three markers, since none of the slopes of the linear
regressions, calculated according to the method of
Bland & Altman (8), was significantly different from
zero. Good agreement between the three markers is
also indicated by the fact that there was no improve-
ment in accuracy in distinguishing premenopausal and
postmenopausal women when total deoxypyridinoline,
type I collagen N-terminal telopeptide and type I colla-
gen C-terminal telopeptide were used in series (i.e. a
result is positive when both test results are above the
threshold value) or in parallel (i. e. a result is positive
when at least one test result is above the threshold
value) (tab. 3).
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Fig. l Urinary excretion of
a) type I collagen N-terminal telopeptide/creatinine,
b) type I collagen C-terminal telopeptide/creatinine in premeno-
pausal and postmenopausal women and
c) total deoxypyridinoline/creatinine.
Results are mean ± SD. For all three markers postmenopausal
women showed a significantly larger excretion than premenopausal
women (p < 0.001).
Discussion
When measured in urine, a biochemical marker of
bone resorption ideally has the four following proper-
ties.
1) Bone specificity.
2) Specificity for bone resorption.
3) Absence of metabolism and clearance from the
body only by the kidney.
4) Specificity, sensitivity, reproducibility and simplicity
of the assay.
A marker with such characteristics would be highly
accurate in distinguishing subjects with different bone
resorption rates. Hydroxyproline is neither specific for
bone (9—12) nor for bone resorption (10), moreover
it is mostly metabolised before being excreted in urine
(13). As a consequence hydroxyproline is a poor bone
resorption marker (1). In the search of specific mark-
ers of bone resorption, different molecules have been
proposed in recent years. In particular, great interest
has been shown in the study of pyridinium cross-
links and of type I collagen telopeptides. Regarding
pyridinium cross-links, pyridinoline is present in many
different tissues (14) and deoxypyridinoline has been
detected in bone, dentine, aorta and ligaments (15).
Both molecules are formed during collagen maturation,
and are therefore released from tissues only following
collagen degradation. Nothing is known about the pres-
ence or absence of metabolism, or the extent of renal
excretion of these molecules. In particular, since uri-
nary pyridinium cross-links are 40% free and 60%
peptide-bound (16), we do not know whether they are
released from bone in this proportion, or whether
they become free due to the action of circulating
or renal peptidases. Total pyridinium cross-links are
measured by HPLC with an assay that is specific
Tab. 1 Accuracies (mean ± SEM) and discriminating powers (Z
score) of total deoxypyridinoline/creatinine, type I collagen N-ter-
minal telopeptide/creatinine and type I collagen C-terminal telo-
peptide/creatinine in distinguishing postmenopausal subjects from
premenopausal subjects.
Total deoxy-
pyridinoline/
creatinine
Accuracy Z score
Type I collagen
N-terminal
telopeptide/
creatinine
Accuracy Z score
Type I collagen
C-terminal
telopeptide/
creatinine
Accuracy Z score
70.8 ±4.9 4.21 66.8 ±5.1 3.54 76.8 ± 4.3 5.67
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Tab. 2a Coefficients of correlation (r) among absolute values of
total deoxypyridinoline, type I collagen N-terminal telopeptide and
type I collagen C-terminal telopeptide. Data are expressed as
nmol/1 (total deoxypyridinoline and Type I collagen N-terminal tel-
opeptide) or μg/l (Type I collagen C-terminal telopeptide). All co-
efficients are highly significant (p < 0.001, n = 113).
Total deoxy-
pyridinoline
Type I collagen
C-terminal
telopeptide
Type I collagen 0.775
N-terminal telopeptide
Type I collagen 0.612
C-terminal telopeptide
0.713
Tab. 2b Coefficients of correlation (r) among total deoxypyrid-
inoline/creatinine, type I collagen N-terminal telopeptide/creatinine
and type I collagen C-terminal telopeptide/creatinine. Data are ex-
pressed as umol/mol of creatinine (total deoxypyridinoline and
type I collagen N-terminal telopeptide) or μg/mol of creatinine
(type I collagen C-terminal telopeptide). All coefficients are highly
significant (p < 0.0001, n = 113).
Total deoxy-
pyridinoline/
creatinine
Type I collagen
C-terminal
telopeptide/
creatinine
Type 1 collagen N-terminal 0.549
telopeptide/creatinine
Type I collagen C-terminal 0.502
telopeptide/creatinine
0.681
and sensitive, but time-consuming (3). Type I collagen
telopeptides are present in all tissues that contain ty-
pe I collagen (4, 5), the largest portion being bone.
The method used to measure type I collagen N-termi-
nal telopeptide uses the cross-linked telopeptide as the
antigen (4); therefore the measured type I collagen N-
terminal telopeptides arise from mature collagen de-
gradation. The method used to measure type I collagen
C-terminal telopeptide uses, as the antigen, a synthetic
peptide corresponding to eight amino acids of the C-
terminal telopeptide of the c^ chain of type I collagen,
and it does not contain a pyridinium cross-link (5);
therefore the possibility of measuring peptides that
derive from collagen that was degraded before deposi-
tion cannot be excluded a priori. Very little is known
about the fate of the telopeptides after their release
from tissues. In this regard, a recent study has shown
that type I collagen N-terminal telopeptide is released
as such from bone resorbed by osteoclasts (17). Type I
collagen N-terminal telopeptide and type I collagen C-
terminal telopeptide are measured by immunoenzymo-
metric assays, which are specific, sensitive, fairly re-
producible and simple (4, 5). Altogether these data
show that total deoxypyridinoline, type I collagen N-
terminal telopeptide and type I collagen C-terminal tel-
opeptide fulfil part of the requirements for an ideal
bone resorption marker. In this study we evaluated
whether these tests were able to distinguish different
rates of bone resorption. For this purpose, we eval-
A -2 -1 0 1 2 · 3 4
Mean type I collagen N-terminal
·- m 4
$t 2Ο ο.
Sj oD) _
S CO τ
.E'2
° Ε
"m Ά -4
b
"°"~ΐ
π
ί^Ο tfr ρ Q
υ Π
D CD D Π
D
0 1 2 3 4
Mean type I collagen
C-terminal - N-terminal telopeptide
- 1 0 1 2 3
Mean type I collagen C-terminal
telopeptide - deoxyoyridinoline
Fig. 2 Linear regression between the difference Δ of the t score
and the mean t score calculated in postmenopausal women for total
deoxypyridinoline/creatinine, type I collagen N-terminal telopep-
tide/creatinine and type I collagen C-terminal telopeptide/creati-
nine, (n = 61),
a: type I collagen N-terminal telopeptide/creatinine - total deoxy-
pyridinoline/creatinine: r = 0.08, p = 0.52;
b: type I collagen N-terminal telopeptide/creatinine — type I colla-
gen C-terminal telopeptide/creatinine: r = —0.07, p = 0.58;
c: total deoxypyridinoline/creatinine - type I collagen C-terminal
telopeptide/creatinine: r = 0.15, p = 0.26).
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Tab. 3 Accuracies (mean ± SEM), in distinguishing premeno-
pausal and postmenopausal women, of the combined use of total
deoxypyridinoline/creatinine, type I collagen N-terminal telopep-
tide/creatinine and type I collagen C-terminal telopeptide/creati-
In series In parallel
69.4 ± 4.9
69.7 ± 4.9
Type I collagen N-terminal 49.1 ± 5.5
telopeptide/creatinine
+ type I collagen C-terminal
telopeptide/creatinine
Type I collagen N-terminal 48.7 ± 5.5
telopeptide/creatinine + total
deoxypyridinoline/creatinine
Type I collagen C-terminal 51.2 ± 5.5
telopeptide/creatinine + total
deoxypyridinoline/creatinine
uated the accuracy and the discriminating power of
the tests in distinguishing a group of women in early
postmenopause, i. e. a group of subjects with a moder-
ate increase in bone resorption rate, from a group of
premenopausal women, i.e. a group of subjects with
a normal bone resorption rate.
Accuracy defines how often a test is able to place
correctly a subject in the group he or she belongs to
for a certain characteristic, in our case the bone re-
sorption rate (18). The major factors that influence the
estimate of the accuracy of a test are the "true disease
status" (in our case the moderately increased bone
resorption rate in the postmenopausal group) and the
decision biases (19). Regarding the "true disease
status", a moderate increase in bone resorption rate
has been shown for women after menopause (20),
which in turn determines an increase in the urinary
excretion of the markers tested in this study (5, 21 —
23). Regarding the decision biases, the receiver oper-
ated characteristic (ROC) curve analysis, that estimates
the accuracy of a test using different threshold values,
avoids such an interfering factor (19). Type I collagen
C-terminal telopeptide, type I collagen N-terminal telo-
peptide and total deoxypyridinoline showed a compar-
atively high accuracy in placing the premenopausal
subjects in the group with normal bone resorption rate
and the postmenopausal subjects in the group with a
moderately increased bone resorption rate. The accura-
cies ranged from 66.8 ± 5.1% for type I collagen N-
terminal telopeptide/creatinine to 76.8 ± 4.3% for ty-
pe I collagen C-terminal telopeptide/creatinine, and
were not significantly different.
The discriminating power, on the other hand, defines
how well a test distinguishes two groups of subjects
that differ for a certain characteristic, which in our
case was again the bone resorption rate. The test
with the highest discriminating power will be the
test that shows the highest difference between the
mean of the two groups with the lowest dispersion.
A Z score higher than 3 defines a high discriminating
power. The differences between the mean of the
premenopausal and postmenopausal groups were not
similar for total deoxypyridinoline/creatinine, type I
collagen N-terminal telopeptide/creatinine and type I
collagen C-terminal telopeptide/creatinine, ranging
from 31% for type I collagen N-terminal telopeptide/
creatinine to 65% for type I collagen C-terminal
telopeptide/creatinine. However, the estimated discrim-
inating powers were not significantly different, sug-
gesting that the tests that show the biggest difference
between the mean of the two groups have also a
bigger dispersion around the mean. Since all the as-
says employed in this study have similar coefficients
of variation (CV < 10%), these differences in variabil-
ity might rather be due to the biological variance of
the markers.
The secondary aim of this study was to evaluate the
relationships among the markers tested. To do so, we
used both the urinary concentrations of the markers
and the creatinine ratio, to ensure that the relationships
among the markers were not influenced by their rela-
tionship with creatinine excretion and by sample dilu-
tion. All markers were highly correlated both when
absolute values and creatinine ratios were used, con-
firming previous publications (4, 5, 21, 24, 25).
Finally, we evaluated the extent of agreement among the
results obtained with the three different tests. For this
purpose, we used the method of Bland & Altman (8)
which evaluates the agreement of two tests by calculat-
ing the linear regression between the mean of the two
tests (independent variable) and the difference of the two
tests (dependent variable). A non-significant regression
shows that the two tests analysed are in good agreement.
To normalize the results obtained with total deoxypyri-
dinoline, type I collagen N-terminal telopeptide and ty-
pe I collagen C-terminal telopeptide, we calculated for
each assay and each postmenopausal woman a t score,
and we used the mean and the difference of the t scores
in the linear regression. The calculated linear regression
(8) showed a non-significant slope for all markers, dem-
onstrating that the results obtained with type I collagen
N-terminal telopeptide, type I collagen C-terminal telo-
peptide and total deoxypyridinoline are in good agree-
ment.
In conclusion we showed that the new immunoenzymo-
metric assays that measure N-terminal and C-terminal
telopeptides of type I collagen have the same accuracy
and discriminating power of the HPLC assay for total
deoxypyridinoline in distinguishing subjects with mod-
erately increased bone resorption rate from normal sub-
jects. Our data on the relationship among these three
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markers show that these markers are correlated and in
good agreement, thus supporting the use of all these as-
says for estimting bone resorption in the diagnosis and
follow-up of osteoporosis.
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